TrialThe Lancet. Oncology2017

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

Stephen J Luen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.